# Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

> **NCT05565417** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Immunitas Therapeutics** · enrollment: 67 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Triple Negative Breast Cancer
- Cutaneous Squamous Cell Carcinoma
- Hormone Receptor Positive Breast Carcinoma
- Small Bowel Cancer
- Esophageal Cancer
- Colorectal Cancer
- Diffuse Large B Cell Lymphoma
- Hodgkin Lymphoma
- Burkitt Lymphoma
- Follicular Lymphoma

## Interventions

- **DRUG:** IMT-009
- **COMBINATION_PRODUCT:** Fruquintinib

## Key facts

- **NCT ID:** NCT05565417
- **Lead sponsor:** Immunitas Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-28
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05565417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05565417, "Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05565417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*